Laboratory Medicine Center, Clinical Research Institute, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
Center for Rehabilitation Medicine, Department of Pain Management, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, 310014, Zhejiang, China.
J Nanobiotechnology. 2023 Mar 3;21(1):77. doi: 10.1186/s12951-023-01827-0.
Nanomedicine technology is a rapidly developing field of research and application that uses nanoparticles as a platform to facilitate the diagnosis and treatment of diseases. Nanoparticles loaded with drugs and imaging contrast agents have already been used in clinically, but they are essentially passive delivery carriers. To make nanoparticles smarter, an important function is the ability to actively locate target tissues. It enables nanoparticles to accumulate in target tissues at higher concentrations, thereby improving therapeutic efficacy and reducing side effects. Among the different ligands, the CREKA peptide (Cys-Arg-Glu-Lys-Ala) is a desirable targeting ligand and has a good targeting ability for overexpressed fibrin in different models, such as cancers, myocardial ischemia-reperfusion, and atherosclerosis. In this review, the characteristic of the CREKA peptide and the latest reports regarding the application of CREKA-based nanoplatforms in different biological tissues are described. In addition, the existing problems and future application perspectives of CREKA-based nanoplatforms are also addressed.
纳米医学技术是一个快速发展的研究和应用领域，它利用纳米粒子作为平台来促进疾病的诊断和治疗。载药和成像对比剂的纳米粒子已经在临床上得到应用，但它们本质上是被动的递送载体。为了使纳米粒子更智能，一个重要的功能是主动定位目标组织的能力。这使纳米粒子能够在目标组织中更高浓度地积累，从而提高治疗效果并降低副作用。在不同的配体中，CREKA 肽（Cys-Arg-Glu-Lys-Ala）是一种理想的靶向配体，对不同模型中过度表达的纤维蛋白具有良好的靶向能力，如癌症、心肌缺血再灌注和动脉粥样硬化。在这篇综述中，描述了 CREKA 肽的特性以及基于 CREKA 的纳米平台在不同生物组织中的最新应用报告。此外，还讨论了基于 CREKA 的纳米平台的现有问题和未来应用前景。
